Learn About Pulmonary Fibrosis
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Mcv Associated Physicians
Patricia Sime is a Pulmonary Medicine provider in Richmond, Virginia. Dr. Sime is rated as an Elite provider by MediFind in the treatment of Pulmonary Fibrosis. Her top areas of expertise are Pulmonary Fibrosis, Pneumonia, Idiopathic Pulmonary Fibrosis, and Acute Interstitial Pneumonia. Dr. Sime is currently accepting new patients.
USC Care Medical Group Inc
Toby Maher is a Pulmonary Medicine provider in Los Angeles, California. Dr. Maher is rated as an Elite provider by MediFind in the treatment of Pulmonary Fibrosis. His top areas of expertise are Acute Interstitial Pneumonia, Interstitial Lung Disease, Pulmonary Fibrosis, Lung Transplant, and Tissue Biopsy.
Inova Health Care Services
Steven Nathan is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Falls Church, Virginia. Dr. Nathan is rated as an Elite provider by MediFind in the treatment of Pulmonary Fibrosis. His top areas of expertise are Acute Interstitial Pneumonia, Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Lung Transplant, and Prostatectomy. Dr. Nathan is currently accepting new patients.
Summary: The goal of this clinical trial is to learn if the investigational drug CAL101 can help prevent further decline in lung function in adults with Idiopathic Pulmonary Fibrosis. Researchers will compare CAL101 with placebo to compare change from baseline in forced vital capacity (FVC). Participants will be randomly assigned to a study group that will receive an IV infusion of either the study medicat...
Summary: The Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry started recruiting in 2014 with the objective of studying Idiopathic Pulmonary Fibrosis. In 2018, the registry expanded to include recruitment of participants with other chronic fibrosing interstitial lung diseases (ILDs) with progressive phenotype also referred to as progressive fibrosing interstitial lung diseases in the C...